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Abstract
Background: Microscopic polyangiitis (MPA), which is classified as an anti-neutrophil cytoplasmic antibody (ANCA)-
associated small vessel vasculitis, is one of the most frequent primary vasculitides in Japan. We earlier nominated 16
genes (IRF7, IFIT1, IFIT5, OASL, CLC, GBP-1, PSMB9, HERC5, CCR1, CD36, MS4A4A, BIRC4BP, PLSCR1, DEFA1/DEFA3, DEFA4,
and COL9A2) as predictors of response to remission induction therapy against MPA. The aim of this study is to
determine the accuracy of prediction using these 16 predictors.
Methods: Thirty-nine MPA patients were selected randomly and retrospectively from the Japanese nationwide
RemIT-JAV-RPGN cohort and enrolled in this study. Remission induction therapy was conducted according to the
Guidelines of Treatment for ANCA-Associated Vasculitis published by the Ministry of Health, Labour, and Welfare
of Japan. Response to remission induction therapy was predicted by profiling the altered expressions of the 16
predictors between the period before and 1 week after the beginning of treatment. Remission is defined as the
absence of clinical manifestations of active vasculitis (Birmingham Vasculitis Activity Score 2003: 0 or 1 point).
Persistent remission for 18 months is regarded as a “good response,” whereas no remission or relapse after
remission is regarded as a “poor response.”
Results: “Poor” and “good” responses were predicted in 7 and 32 patients, respectively. Five out of 7 patients with
“poor” prediction and 1 out of 32 patients with “good” prediction experienced relapse after remission. One out of 7
patients with “poor” prediction was not conducted to remission. Accordingly, the sensitivity and specificity to
predict poor response was 85.7% (6/7) and 96.9% (31/32), respectively.
Conclusions: Response to remission induction therapy can be predicted by monitoring the altered expressions of
the 16 predictors in the peripheral blood at an early point of treatment in MPA patients.
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Background
Microscopic polyangiitis (MPA), which is classified as an
anti-neutrophil cytoplasmic antibody (ANCA)-associated
small vessel vasculitis [1], is one of the most frequent
primary vasculitides in East Asia. In Japan, Ozaki et al.
conducted a prospective clinical trial on newly diagnosed
patients with MPA in which they were administered the
remission induction therapy according to disease seve-
rity [2]. Briefly, the MPA patients were stratified into
three categories based on disease severity, namely mild
form, severe form, and most severe form. The mild form
included patients with slight disorder of one or more or-
gans, a renal-limited type (except rapidly progressive
glomerulonephritis (RPGN)), and a pulmonary-limited
type (except pulmonary hemorrhage). The severe form
consisted of patients with a generalized type (MPA with
involvement of more than two organs), pulmo-renal type
(glomerulonephritis plus either limited pulmonary
hemorrhage or extended interstitial pneumonia), and
RPGN. The most severe form included patients with dif-
fuse alveolar hemorrhage, intestinal perforation, acute
pancreatitis, cerebral hemorrhage, or concurrent pres-
ence of anti-glomerular basement membrane antibodies.
After the establishment of diagnosis, the patients were
treated according to the following protocols. 1) The mild
form: low-dose corticosteroids (0.3–0.6 mg/kg/day) were
administered; oral immunosuppressive agents (cyclo-
phosphamide or azathioprine, 0.5–1.0 mg/kg/day or 25–
75 mg/day, respectively) were optional. 2) The severe
form: high-dose corticosteroids (0.6–1.0 mg/kg/day) and
oral cyclophosphamide (0.5–2.0 mg/kg/day) were given;
intravenous methylprednisolone (0.5–1.0 g/day for
3 days) was considered as an alternative. Instead of oral
administration, the use of intravenous cyclophosphamide
(0.5–0.75 g/m2 monthly) was also allowed. 3) Most se-
vere form: plasmapheresis (2.0–3.0 L/day for 3 days) was
employed together with the regimen for the severe form
described above.
After 18 months, the outcome of 47 patients, compris-
ing of 22 with mild disease, 23 with severe disease, and 2
with the most severe disease, were analyzed. Remission,
which is defined as the absence of clinical manifestations
of active vasculitis (Birmingham Vasculitis Activity Score
2003: 0 or 1 point), was achieved in 42 out of 47 patients
(remission rate, 89.4%). Among the 42 patients, 8
showed relapse of the disease, which is defined as the re-
currence of at least one manifestation of vasculitis (re-
currence rate, 19.0%). Ultimately, 5 out of 47 patients
died (mortality rate, 10.6%).
These results demonstrate that the suggested thera-
peutic protocols are applicable for patients with MPA,
but the possibility of relapse is indicated and, in the
worst case scenario, death may occur regardless of
the treatment. We have considered that, if response
to the remission induction therapy would be pre-
dicted at an early point during the therapy, meticu-
lous follow-up or application of additional regimens
to the treatment could expectedly improve the
outcome. For this purpose, we focused on the typical
alteration of gene expressions after treatment in
“good responders” who were conducted to persistent
remission. We considered the prediction of “poor re-
sponders” who would not be conducted to remission
or would relapse after remission when such typical
alteration of gene expressions was not observed in
the peripheral blood. Based on the results obtained
through the transcriptome analysis, we nominated 16
genes from the comprehensive 8793 genes as predic-
tors of response to remission induction therapy in
MPA [3]. The 16 predictors included interferon (IFN)
regulatory factor (IRF)7, IFN-induced protein with tet-
ratricopeptide repeats (IFIT)1, IFIT5, 2′-5′-oligoadeny-
late synthetase-like (OASL), Charcot-Leyden crystal
protein (CLC), guanylate binding protein 1 (GBP-1),
proteasome (prosome macropain) subunit, beta type, 9
(PSMB9), hect domain and RLD (HERC)5, chemokine
(C-C motif ) receptor 1 (CCR1), CD36, membrane-
spanning 4-domains, subfamily A, member 4 (MS4A4A),
XIAP-associated factor-1 (BIRC4BP), phospholipid
scramblase 1 (PLSCR1), defensin α1 and α3 (DEFA1/
DEFA3), defensin α4 (DEFA4), and collagen type IX
α2 (COL9A2).
In the present study, we determined the accuracy of
prediction with the use of the aforementioned 16 predic-
tors on 39 MPA patients who were selected randomly
and retrospectively from the Japanese nationwide
RemIT-JAV-RPGN cohort [4].
Methods
Patient cohorts
Currently in Japan, there are two nationwide cohorts
of vasculitides, namely the JMAAV cohort [2] and
RemIT-JAV-RPGN cohort [4]. In the JMAAV cohort,
diagnosis of MPA was made according to the
diagnostic criteria for MPA of the Research Group of
Intractable Vasculitis, the Ministry of Health, Labour,
and Welfare (MHLW) of Japan [5], whereas the
diagnostic algorithm for primary systemic vasculitis
proposed by the European Medicines Agency (EMEA)
[6] was adopted in the RemIT-JAV cohort. Although
some patients diagnosed as MPA according to the
Japanese MHLW criteria were categorized into granu-
lomatosis with polyangiitis (GPA) in the EMEA
algorithm, most patients categorized into MPA in the
EMEA algorithm were also diagnosed as MPA accor-
ding to the Japanese MHLW criteria [7]. Therefore, it
is conceivable that MPA patients in the RemIT-JAV-
RPGN cohort appear to manifest a typical phenotype
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of MPA. In both cohorts, only patients without any
prior treatment for MPA were enrolled. Patients in
the RemIT-JAV-RPGN cohort received remission in-
duction therapy according to the Japanese MHLW
Guidelines of Treatment for ANCA-Associated Vascu-
litis that was reflected in the JMAAV protocol.
Thirty-nine MPA patients were selected randomly and
retrospectively from the RemIT-JAV-RPGN cohort
and included in this study. The baseline characteris-
tics of these MPA patients and the given remission
induction therapy are shown in Table 1. Written
informed consent was obtained from all the patients
at their respective institutes where they were being
treated. The study protocol was approved by the re-
spective institutional ethics committees.
Blood samples and gene expression profiling
Peripheral blood samples (10 mL) were obtained before
and 1 week after the beginning of remission induction
therapy. Total RNAs were extracted using the PAXgene
Blood RNA System (BD, Franklin Lakes, NJ, USA). High
throughput real-time reverse transcription polymerase
chain reaction (PCR; Applied Biosystems, Carlsbad, CA,
USA) was applied to quantify the expression of the 16
genes (IRF7, IFIT1, IFIT5, OASL, CLC, GBP-1, PSMB9,
HERC5, CCR1, CD36, MS4A4A, BIRC4BP, PLSCR1,
DEFA1/DEFA3, DEFA4, and COL9A2) which were iden-
tified as predictors in the earlier study [3].
Regression formula for the prediction index that
represents response to remission induction therapy
Prior to this study, we have determined the regression
formula that reflected the altered expression of the 16
genes by remission induction therapy and the response
to the therapy by employing 22 MPA patients from the
JMAAV cohort. For this purpose, the Ct value of real-
time PCR was applied. The Ct value represents the cycle
number in which the PCR products reach the threshold
level. The expression level of the target gene was shown
as ΔCt (ΔCt = Ct value of the target gene – Ct value of
the housekeeping β-actin gene). Next, the changed
amount of expression of the target gene by the treat-
ment was shown as ΔΔCt (ΔΔCt = ΔCt 1 week after the
beginning of treatment – ΔCt before treatment). It is
considered that when ΔΔCt is 1, the expression level of
the target gene before treatment is twofold higher than
1 week after the beginning of treatment. Accordingly,
when the expression level of the target gene before treat-
ment is set as 1, the fold-expression of the target gene
1 week after the beginning of treatment is shown as
2–ΔΔCt. Subsequently, the response to the treatment was
replaced by a dummy number, wherein “good response
(persistent remission)” was regarded as 0 and “poor
response (relapse after remission or no remission)” was
regarded as 1. After these preparations, multiple regres-
sion analysis was conducted concerning the 22 MPA
patients, including 17 good responders and 5 poor
Table 1 Baseline characteristics of MPA patients and given remission induction therapy
*p < 0.05 vs mild form
BVAS Birmingham Vasculitis Activity Score, MPA microscopic polyangiitis, SD standard deviation
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responders (4 patients relapsed after remission and
remission was not achieved in 1 patient).
Prediction of response to remission induction therapy
In this analysis, response to the remission induction
therapy was replaced by dummy numbers, 0 and 1,
wherein 0 means “good response” and 1 means “poor re-
sponse.” For the next discrimination analysis, we plotted
the receiver operating characteristic (ROC) curve. How-
ever, the ROC curve was not suitable for this case (data
not shown). Thus, we determined the boundary value as
the mean value of the expected prediction indices of the
22 patients. Since 0 was applied to 17 patients and 1 was
applied to 5 patients, the mean value of the total of 22
patients was 0.23. Therefore, the prediction index of less
than 0.23 predicts “good response,” whereas the value
greater than 0.23 predicts “poor response.”
Discrimination analysis
The accuracy of prediction was evaluated by employing
another 39 MPA patients who were selected randomly
and retrospectively from the RemIT-JAV-RPGN cohort.
These patients were completely different from those en-
rolled in the derivation of the regression formula for the
prediction index.
Results
Determination of regression formula for the prediction
index that represents response to remission induction
therapy
In our earlier study, we conducted the comprehensive
transcriptome analysis using peripheral blood samples
obtained before and 1 week after the beginning of remis-
sion induction therapy on 12 MPA patients selected ran-
domly from the JMAAV cohort (Cohort 1) [3]. Results
demonstrated that the expressions of 88 genes were
significantly altered after the treatment in 9 “good re-
sponders.” This characteristic alteration of gene expres-
sion was not observed in 3 “poor responders.” We
selected 30 genes that showed the statistically top values
among the 88 genes.
Next, in order to identify the most valuable genes for
prediction of response to the treatment, the logistic re-
gression analysis with stepwise method was carried out
on the 30 genes using the add-in Excel software 2012.
For this purpose, we employed another cohort, Cohort
2, selected randomly from the JMAAV patients. In brief,
16 genes were selected randomly from the 30 genes at
first, and then the influence of the genes on the predic-
tion was calculated. Thereafter, the gene which showed
the minimum influence on the prediction was replaced
by another gene among the remaining 14 genes. This
operation was repeated until all genes were used. Subse-
quently, the gene with the minimum influence on the
prediction was excluded one by one until the last gene
remained. All combinations of genes were examined for
prediction of the response to the treatment. Ultimately,
the 16 genes, including IRF7, IFIT1, IFIT5, OASL, CLC,
GBP-1, PSMB9, HERC5, CCR1, CD36, MS4A4A, BIRC4BP,
PLSCR1, DEFA1/DEFA3, DEFA4, and COL9A2, were
nominated as the most valuable genes for prediction and,
at the same time, the regression formula for prediction of
response to remission induction therapy was determined
as follows. The contribution of the 16 genes to prediction
is shown in Table 2.
Prediction index = 0.84 + (0.74) × (2–ΔΔCt of IRF7)
+ (–0.32) × (2–ΔΔCt of IFIT1) + (–1.44) × (2–ΔΔCt of
IFIT5) + (–0.18) × (2–ΔΔCt of OASL) + (0.05) × (2–ΔΔCt
of CLC) + (–0.84) × (2–ΔΔCt of GBP1) + (0.38) × (2–ΔΔCt of
PSMB9) + (0.37) × (2–ΔΔCt of HERC5) + (–0.91) × (2–ΔΔCt of
CCR1) + (–0.84) × (2–ΔΔCt of CD36) + (0.43) × (2–ΔΔCt of
MS4A4A) + (0.93) × (2–ΔΔCt of BIRC4BP) + (0.72) × (2–ΔΔCt
of PLSCR1) + (0.01) × (2–ΔΔCt of DEFA1/DEFA3) + (–
0.02) × (2–ΔΔCt of DEFA4) + (–0.06) × (2–ΔΔCt of COL9A2).
Relevance of regression formula and boundary value for
the prediction of response to remission induction therapy
In order to determine the relevance of the regression
formula and the boundary value for the prediction of
response to remission induction therapy, we plotted the
prediction indices and actual responses of the 22 train-
ing samples together with the boundary value (Fig. 1).
Results demonstrate the relevance of the regression
formula and the boundary value for prediction.
Table 2 Contribution of 16 genes to prediction
Coefficient Standard error P value
Intercept 0.84 0.16 0.004
IRF7 0.74 0.17 0.008
IFIT1 –0.32 0.09 0.015
IFIT5 –1.43 0.21 0.001
OASL –0.18 0.16 0.301
CLC 0.05 0.02 0.037
GBP1 –0.84 0.20 0.009
PSMB9 0.38 0.35 0.321
HERC5 0.37 0.10 0.013
CCR1 –0.91 0.26 0.012
CD36 –0.84 0.26 0.024
MS4A4A 0.43 0.21 0.099
BIRC4BP 0.93 0.09 0.000
PLSCR1 0.72 0.27 0.047
DEFA/DEFA3 0.01 0.01 0.367
DEFA4 –0.02 0.02 0.311
COL9A2 –0.06 0.02 0.015
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Accuracy of prediction of response to remission induction
therapy
To evaluate the accuracy of prediction, the correlation
between prediction indices and actual responses to the
remission induction therapy was analyzed concerning
the next 39 MPA patients (Fig. 2). As a result, “poor”
and “good” responses were predicted in 7 and 32 pa-
tients, respectively (Table 3). Five out of 7 patients with
“poor” prediction and 1 out of 32 patients with “good”
prediction experienced relapse after remission. One out
of 7 patients with “poor” prediction was not conducted
to remission. Accordingly, the sensitivity and specificity
to predict poor response was 85.7% (6/7) and 96.9% (31/
32), respectively. We determined the 95% confidence in-
tervals of the sensitivity and specificity as 0.421–0.996
and 0.838–0.999, respectively.
Table 4 demonstrates the detailed results with regard
to disease severity. The overall accuracy of prediction is
94.9%, while the accuracy tends to decline as the disease
severity increases.
Discussion
Lyons and colleagues reported that the transcriptome
analysis of leukocyte subsets before treatment enabled
the identification of gene signatures of ANCA-associated
vasculitis, including MPA [8]. Similarly, McKinney et al.
reported that the transcription signature of CD8+ T cells
before treatment could predict prognosis in autoimmune
diseases, including MPA [9]. On the contrary, we have
focused on the altered gene expression in the peripheral
blood of MPA patients between the period before and
1 week after the beginning of remission induction ther-
apy. Therefore, it would seem likely that the prediction
was based on the effects of the therapeutic reagents
included in the remission induction regimen.
Among the 16 genes used as predictors in this study,
the expressions of IRF7, IFIT1, IFIT5, OASL, CLC, GBP-1,
PSMB9, HERC5, CCR1, CD36, MS4A4A, BIRC4BP, and
PLSCR1 were decreased, whereas those of DEFA1/DEFA3,
DEFA4, and COL9A2 were increased after treatment in
“good responders” [3]. The relation between the decrease
in several IFN-related genes, such as IRF7 [10], IFIT1 [11],
IFIT5 [12], OASL [13], and GBP-1 [14], after the anti-
inflammatory immunosuppressive treatment and the
“good response” could be profound. ANCA-associated
vasculitis, including MPA, has not been regarded as a
type 1 IFN-driven disease [8]. We consider the ex-
pressions of the IFN-related genes as very sensitive to
Fig. 1 Relevance of regression formula and boundary value for
prediction of response to remission induction therapy. The prediction
indices and actual responses of the 22 training patients, including 17
“good responders” and 5 “poor responders,” were plotted together
with the boundary value. The boundary value was determined as the
mean value of expected prediction indices of the 22 patients. Since 0
was applied to 17 patients and 1 was applied to 5 patients, the mean
value of the total of 22 patients was 0.23. Therefore, the prediction
index of less than 0.23 predicts “good response,” whereas the value
greater than 0.23 predicts “poor response”
Fig. 2 Prediction indices of 39 MPA patients. The prediction indices
and actual responses of the 39 MPA patients, including 32 “good
responders” and 7 “poor responders,” were plotted together with
the boundary value. Red dots represent patients whose prediction is
inconsistent with actual response
Table 3 Predicted and actual responses to remission induction
therapy against microscopic polyangiitis (n = 39)
Prediction Actual response
Poor Good
Poor 6 1
Good 1 31
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immunosuppressive treatment. Thus, we assume that
the alteration can be a good marker of the thera-
peutic effects, though the expressions are not signa-
tures of the disease.
In addition, we noted that the decrease in CLC gene
expression after treatment reflected the “good response.”
CLC proteins are mainly expressed in eosinophils [15],
and the eosinophil count is rapidly reduced by cortico-
steroid treatment; therefore, the reduction of eosinophils
in the peripheral blood after treatment possibly predicts
“good response.” However, we could not assess the rela-
tion between prediction and alteration of leukocyte
counts or rates of subpopulations in the peripheral blood
after the treatment. This is the limitation of this study.
We hope to challenge the clarification of this issue in
our future studies.
We have demonstrated that the response to remission
induction therapy can be predicted by monitoring the al-
tered expressions of the 16 predictors in the peripheral
blood at an early point of treatment in MPA patients.
On the other hand, the accuracy tends to decline
according to the increase in disease severity, though
there is no statistical power. A significantly bigger
sample size can elucidate the benefits and disadvantages
of the prediction in future studies.
Although improvement to increase the sensitivity to
predict “poor responders” is needed, such prediction at
an early point of treatment, if any, should be significant.
This prediction can help us consider meticulous follow-
up or application of additional regimens to the treat-
ment for the patients who are predicted as “poor
responders.”
Conclusions
The response to remission induction therapy can be pre-
dicted by monitoring the altered expressions of the 16
predictors in the peripheral blood at an early point of
treatment in MPA patients.
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